A Second Dose of GAD-Alum Shows Promise for Extending Type 1 Diabetes Benefits

GAD-alum is an immunotherapy designed to slow the loss of insulin-producing beta cells in Type 1 diabetes. Research has shown it can help preserve residual beta cell function—the remaining ability of the pancreas to produce insulin—in certain people with the condition.

A key challenge with many immunotherapies is that their benefits tend to decrease over time. This raises a question: Could giving a second dose extend the benefits? The DIAGNODE-B pilot trial explored this possibility in a small group of people who had already benefited from an initial course of GAD-alum treatment.

The pilot trial included six participants who had previously received active treatment with intralymphatic GAD-alum—meaning the treatment was injected directly into lymph nodes rather than given by vein or under the skin. All participants carried a specific genetic marker called HLA DR3-DQ2, which earlier research suggested was associated with better response to GAD-alum.

Each participant received one additional 4-microgram dose of GAD-alum. Starting one month before the injection, they also took vitamin D supplementation (2000 U daily) for two months. Researchers followed participants for 12 months, measuring beta cell function using Mixed-Meal Tolerance Tests and tracking clinical outcomes like HbA1c, time in range, and daily insulin requirements.

Over the 12-month follow-up period, C-peptide—a marker of beta cell function—decreased only minimally in the participants. Most showed stable HbA1c levels and stable IDAA1c (a combined measure of blood sugar control and insulin use).

The average time in target blood sugar range increased, and the average daily insulin dose decreased at the 12-month follow-up compared to the baseline. These changes suggest participants may have experienced improved diabetes management over the year of follow-up.

Redosing with GAD-alum appeared to be safe and well-tolerated across the small group studied, with no new safety signals raised during the trial.

While these pilot results are encouraging, it's important to remember this was a very small study with only six participants. The researchers conclude that redosing with GAD-alum 'seems to be safe and tolerable, and may prolong the disease modification' from the original treatment. Larger, confirmatory studies would be needed to determine whether redosing is truly effective for extending GAD-alum's benefits and to identify who might benefit most from this approach.

Source: International journal of molecular sciences. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.